Accessibility Menu
Harmony Biosciences logo

Harmony Biosciences

(NASDAQ) HRMY

Current Price$27.84
Market Cap$1.61B
Since IPO (2020)-25%
5 Year-11%
1 Year-19%
1 Month-25%

Harmony Biosciences Financials at a Glance

Market Cap

$1.61B

Revenue (TTM)

$868.45M

Net Income (TTM)

$158.69M

EPS (TTM)

$2.71

P/E Ratio

10.28

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$27.84

Volume

27,703

Open

$27.66

Previous Close

$27.84

Daily Range

$27.12 - $28.12

52-Week Range

$25.52 - $40.87

HRMY: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Harmony Biosciences

Industry

Pharmaceuticals

Employees

293

CEO

Jeffrey M. Dayno, MD

Headquarters

Plymouth Meeting, PA 19462, US

HRMY Financials

Key Financial Metrics (TTM)

Gross Margin

77%

Operating Margin

24%

Net Income Margin

18%

Return on Equity

21%

Return on Capital

20%

Return on Assets

12%

Earnings Yield

9.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.61B

Shares Outstanding

57.84M

Volume

27.70K

Short Interest

0.00%

Avg. Volume

849.02K

Financials (TTM)

Gross Profit

$670.11M

Operating Income

$208.47M

EBITDA

$255.05M

Operating Cash Flow

$348.20M

Capital Expenditure

$310.00K

Free Cash Flow

$347.89M

Cash & ST Invst.

$775.34M

Total Debt

$239.58M

Harmony Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$243.78M

+21.1%

Gross Profit

$175.23M

+19.3%

Gross Margin

71.88%

N/A

Market Cap

$1.61B

N/A

Market Cap/Employee

$6.01M

N/A

Employees

268

N/A

Net Income

$22.49M

-54.6%

EBITDA

$51.74M

-22.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$535.76M

+87.5%

Accounts Receivable

$96.79M

+16.6%

Inventory

$5.36M

-25.6%

Long Term Debt

$152.69M

-6.8%

Short Term Debt

$86.89M

+394.6%

Return on Assets

12.48%

N/A

Return on Invested Capital

20.45%

N/A

Free Cash Flow

$126.04M

+67.9%

Operating Cash Flow

$126.15M

+67.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SIONSionna Therapeutics, Inc.
$35.49+3.17%
IMCRImmunocore Holdings plc
$30.04+0.00%
NUVBNuvation Bio Inc.
$4.26-0.47%
AUPHAurinia Pharmaceuticals Inc.
$14.07-0.07%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$178.56-0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$45.69-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.35+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.97-0.06%

Questions About HRMY

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.